Safety Assessment of
Ethers and Esters of Ascorbic Acid as Used in Cosmetics

Status: Scientific Literature Review for Public Comment
Release Date: October 11, 2016
Panel Date: December 5-6, 2016

All interested persons are provided 60 days from the above date to comment on this safety assessment and to identify additional published data that should be included or provide unpublished data which can be made public and included. Information may be submitted without identifying the source or the trade name of the cosmetic product containing the ingredient. All unpublished data submitted to CIR will be discussed in open meetings, will be available at the CIR office for review by any interested party and may be cited in a peer-reviewed scientific journal. Please submit data, comments, or requests to the CIR Director, Dr. Lillian J. Gill.

The 2016 Cosmetic Ingredient Review Expert Panel members are: Chair, Wilma F. Bergfeld, M.D., F.A.C.P.; Donald V. Belsito, M.D.; Ronald A. Hill, Ph.D.; Curtis D. Klaassen, Ph.D.; Daniel C. Liebler, Ph.D.; James G. Marks, Jr., M.D.; Ronald C. Shank, Ph.D.; Thomas J. Slaga, Ph.D.; and Paul W. Snyder, D.V.M., Ph.D. The CIR Director is Lillian J. Gill, D.P.A. This report was prepared by Wilbur Johnson, Jr., M.S., Senior Scientific Analyst, Ivan Boyer, Ph.D., Senior Toxicologist, and Bart Heldreth, Ph.D., Chemist.
INTRODUCTION

The safety of the following 7 Ethers/Esters of Ascorbic Acid ingredients as used in cosmetics is reviewed in this safety assessment:

Tetrahexyldecyl Ascorbate
Ascorbyl Isostearate
Ascorbyl Linoleate
Ascorbyl Tetraisopalmitate
Ascorbyl Palmitate
Ascorbyl Dipalmitate
Ascorbyl Stearate

According to the International Cosmetic Ingredient Dictionary and Handbook, the functions of these ingredients in cosmetic products include: antioxidants; skin-conditioning agents; skin protectants; fragrance ingredients; and skin bleaching agents. Ascorbyl Palmitate is the only ingredient with an additional function of fragrance ingredient, and Ascorbyl Linoleate is the only ingredient with an additional function of skin bleaching agent; however, functioning as a skin bleaching agent is not a cosmetic use and, therefore, the Panel did not evaluate safety for that use.

The Panel has evaluated the safety of Ascorbyl Palmitate, Ascorbyl Dipalmitate, and Ascorbyl Stearate in cosmetics, and issued a final report in 1999 with the conclusion that these ingredients are safe in the present practices of use. Safety test data on these ingredients from the final report are summarized in Table 1, and more recent data are included in the report text. The safety of these 3 ingredients is being reevaluated in the current safety assessment, taking into consideration data that have been identified in the published literature since the final report was published. Additionally, it is possible that data on these 3 ingredients may be useful in evaluating the safety, relative to certain toxicity endpoints, of one or more of the remaining 4 ingredients in the current safety assessment. These 4 ingredients, Tetrahexyldecyl Ascorbate, Ascorbyl Isostearate, Ascorbyl Linoleate, and Ascorbyl Tetraisopalmitate are being reviewed for the first time in this safety assessment.

CHEMISTRY

Definition and General Characterization

The ingredients in this report are all alkylated or acylated derivatives of Ascorbic Acid. Ascorbic Acid, also known as Vitamin C, is a reducing agent (a.k.a. antioxidant), is a constituent of normal skin, and found at high levels in both the dermis and epidermis. Fatty-alkyl and fatty-acyl derivatives thereof are lipophilic ingredients.

Figure 1. Ascorbate derivatives, wherein R, independently in each case, is hydrogen, fatty-alkyl or fatty-acyl.

The definitions, structures, and functions in cosmetics of the ethers/esters of ascorbic acid are presented in Table 2.

Chemical and Physical Properties

The chemical and physical properties of ethers/esters of ascorbic acid are presented in Table 3.
**Method of Manufacture**

Fatty acyl ascorbyl derivatives may be synthesized via acylation of vitamin C, by direct means (with fatty acids or small chain esters) or enzymatically (e.g., with certain lipases). The enzymatic process may be preferred since it is easier to control regioselectivity. Polar organic solvents, ionic liquids, and supercritical fluids have been successfully used as reaction media.

**Ascorbyl Tetraisopalmitate**

According to one source, Ascorbyl Tetraisopalmitate (also known as tetra-isopalmitoyl ascorbate or Tetrahexyldecyl Ascorbate) is produced by combining one molecule of vitamin C (ascorbic acid) with four molecules of tetraisopalmitic acid, a fatty acid found that is in butter and other sources.

**Ascorbyl Palmitate**

Ascorbyl Palmitate is prepared by condensing palmitoyl chloride and ascorbic acid in the presence of a dehydrochlorinating agent such pyridine.

**Ascorbyl Stearate**

Ascorbyl Stearate is produced by the reaction of l-ascorbic acid and stearic acid.

**Ascorbyl Palmitate and Ascorbyl Linoleate**

Mixed esters of ascorbic acid have been synthesized using methyl esters of palm and soybean oils as acyl donors, in acetone at 508°C. A conversion of 62% was obtained with palm oil methyl ester at an ascorbic acid to acyl donor molar ratio of 1:4; the mixed ester contained 45.89% Ascorbyl Palmitate, 42.59% ascorbyl oleate, and 10.1% Ascorbyl Linoleate. Acylation with soybean oil methyl ester resulted in 17% conversion, yielding a mixed ester containing 10.08% Ascorbyl Palmitate, 20.68% ascorbyl oleate, and 64.96% of Ascorbyl Linoleate.

**Composition/Impurities**

**Ascorbyl Palmitate and Ascorbyl Stearate**

The National Formulary (NF) states that Ascorbyl Palmitate must contain between 95% and 100.5% of C_{22}H_{38}O_{7}, based on the dried weight. Depending on the method of manufacture, Ascorbyl Palmitate could contain stearic acid, because palmitic acid samples contain large quantities of stearic acid. Likewise, Ascorbyl Stearate could contain palmitic acid. When dried, Ascorbyl Stearate contains not less than 93% of ascorbyl-L-stearate.

The following limitations have been stated in a cosmetics industry specification for Ascorbyl Palmitate: sulfate ash (0.1% minimum), arsenic (as As) (3 ppm maximum), and lead (as Pb) (20 ppm maximum). Another cosmetics industry specification has indicated a 2 ppm maximum limitation for arsenic (as As) in Ascorbyl Stearate.

According to the Joint Food and Agriculture Organization of the United Nations (FAO)/World Health Organization (WHO) Expert Committee on Food Additives, 2 mg/kg is the limit for lead in both Ascorbyl Palmitate and Ascorbyl Stearate as food additives.

**USE**

**Cosmetic**

The safety of the ethers/esters of ascorbic acid included in this safety assessment is evaluated based on data received from the U.S. Food and Drug Administration (FDA) and the cosmetics industry on the expected use of these ingredients in cosmetics. Use frequencies of individual ingredients in cosmetics are collected from manufacturers and reported by cosmetic product category in FDA’s Voluntary Cosmetic Registration Program (VCRP) database. Use concentration data are submitted by the cosmetics industry in response to surveys, conducted by the Personal Care Products Council (Council), of maximum reported use concentrations by product category. The use frequency data indicate that 3 of the 4 ingredients in this safety assessment are currently being used in cosmetic products (See Table 4). The VCRP data that are available indicate that Ascorbyl Isostearate is not being used in cosmetics.
According to 2016 VCRP data, the greatest reported use frequency is for Tetrahexyldecyl Ascorbate (397 formulations, mostly leave-on products) (Table 4). Use concentration data from the cosmetics industry are anticipated.

Cosmetic products containing the ethers/esters of ascorbic acid may be applied to the skin and hair or, incidentally, may come in contact with the eyes and mucous membranes. Additionally, Tetrahexyldecyl Ascorbate and Ascorbyl Tetraisopalmitate are reportedly being used in lipstick products that may result in incidental ingestion. Products containing these ingredients may be applied as frequently as several times per day and may come in contact with the skin or hair for variable periods following application. Daily or occasional use may extend over many years.

Tetrahexyldecyl Ascorbate is used in hair spray, fragrance preparations, and face powders, all of which could possibly be sprayed. In practice, 95% to 99% of the droplets/particles released from cosmetic sprays have aerodynamic equivalent diameters >10 µm, with propellant sprays yielding a greater fraction of droplets/particles below 10 µm, compared with pump sprays. Therefore, most droplets/particles incidentally inhaled from cosmetic sprays would be deposited in the nasopharyngeal and bronchial regions and would not be respirable (i.e., they would not enter the lungs) to any appreciable amount. Conservative estimates of inhalation exposures to respirable particles during the use of loose powder cosmetic products are 400-fold to 1000-fold less than protective regulatory and guidance limits for inert airborne respirable particles in the workplace.

Tetrahexyldecyl Ascorbate is included in the Australian Inventory of Chemical Substances (AICS) with the following conditions of use: (1) for cosmetic use only, (2) for dermal use only, (3) the concentration is not to exceed 1%, and (4) it is not to be included in topical products intended for use in the eye.

Noncosmetic

Ascorbyl Palmitate
and Ascorbyl Stearate

Ascorbyl Palmitate and Ascorbyl Stearate have been approved by FDA as preservatives in margarine, with a concentration limit of 0.02% either individually or in combination. FDA has determined that Ascorbyl Palmitate is generally recognized as safe for use as a preservative in food for human consumption.

The European Food Safety Authority (EFSA) has issued a scientific opinion on the safety and efficacy of vitamin C (ascorbic acid, sodium ascorbate, calcium ascorbate, Ascorbyl Palmitate, sodium calcium ascorbyl phosphate, and sodium ascorbyl phosphate) as a feed additive for all animal species. The EFSA concluded that Vitamin C, in the form of ascorbic acid and its calcium and sodium salts, Ascorbyl Palmitate, sodium calcium ascorbyl phosphate and sodium ascorbyl phosphate, is safe for all animal species. The EFSA also stated that setting a maximum content in feed and water for drinking is not considered necessary.

Ascorbyl Palmitate has been approved by FDA for use as an inactive ingredient in approved drug products.

According to the Environmental Protection Agency (EPA), residues of Ascorbyl Palmitate are exempt from the requirement of a tolerance when used in accordance with good agricultural practice as an inert ingredient in pesticide formulations applied to growing crops or to raw agricultural commodities after harvest. The EPA has also determined that Ascorbyl Palmitate is exempt from the requirement of a tolerance when used in accordance with good agricultural practice as an inert ingredient in pesticide formulations that are applied to animals.

Ascorbyl Tetraisopalmitate

In the Republic of Korea, Ascorbyl Tetraisopalmitate, glabridin, (−)-α-bisabolol, arbutin, niacinamide, ascorbyl glucoside, and ethyl ascorbyl ether are the main ingredients used in cosmetics reported to function as whitening agents. Vitamin C, or L-ascorbic acid, has the ability to inhibit the activity of tyrosinase. Due to oxidation, vitamin C is easily degraded and unstable when exposed to air or light. To overcome this defect, Ascorbyl Tetraisopalmitate and other vitamin C derivatives have been introduced.
TOXICOKINETIC STUDIES

Dermal Penetration

In Vitro

Ascorbyl Palmitate

According to one source, L-ascorbic acid is an unstable molecule to formulate for topical use, and more stable derivatives of L-ascorbic acid have been utilized in topical formulations. Although esters of ascorbic acid are more stable and readily converted to L-ascorbic acid after oral ingestion, it is not clear that derivatives, after topical application, are absorbed into the skin or converted to L-ascorbic acid after penetration. With this in mind, the percutaneous absorption of ascorbic acid (15%; pH 3.2) and its derivatives, Ascorbyl Palmitate (10%) and magnesium ascorbyl phosphate (12%), was evaluated using white Yorkshire pig skin positioned in a semi-occlusive chamber. The two ascorbic acid derivatives were described as commercially available high concentration formulations. Each test substance was applied to the skin for 24 h, after which full-thickness 6-mm punch biopsy specimens of skin were analyzed. Skin levels of L-ascorbic acid were expressed as the mean ± standard deviation (n = 10); p values were expressed versus the control skin. The p value of ascorbic acid versus each formulation was 0.0005. The p values for the Ascorbyl Palmitate and magnesium ascorbyl phosphate ester formulations were 0.3176 and 0.9101, respectively. The p values indicate that neither ester significantly increased L-ascorbic acid skin levels. Referring to earlier publications, it has been noted noted that although Ascorbyl Palmitate appears to readily enter skin, its conversion to L-ascorbic acid may be inefficient. Furthermore, Ascorbyl Palmitate appears to remain on the extracellular surface of cells and may not be readily converted to L-ascorbic acid.

A study was performed to examine the suitability of various colloidal systems for Ascorbyl Palmitate skin delivery using pig ear skin and Franz diffusion cells. One gram of a self-microemulsifying system (mixture of oil and surfactants with water), water-in-oil microemulsion, or liquid crystal loaded with Ascorbyl Palmitate (at 1 % or at maximum solubilization concentration) was applied to the skin surface. After 6 h, the formulation was removed and the skin surface was cleaned. The epidermis was separated from the dermis by heat treatment, and Ascorbyl Palmitate was extracted with methanol. The results of Ascorbyl Palmitate skin deposition showed relatively high concentrations of Ascorbyl Palmitate delivered to skin layers, especially to the epidermis, whereas, no Ascorbyl Palmitate was found in receptor fluid. The highest solubilization capacity for Ascorbyl Palmitate was determined for the oil and surfactant mixture alone. The greatest extent of skin permeation was observed for liquid crystal loaded with 1% Ascorbyl Palmitate. Among the phase transition systems tested, liquid crystal was selected as the best potential carrier for Ascorbyl Palmitate. Additionally, the results of a more recent publication suggest that a lecithin-based liquid crystalline system with a lamellar structure could be used as a physiologically acceptable dermal delivery system for Ascorbyl Palmitate.

Animal

Ascorbyl Dipalmitate

The percutaneous absorption of six different oil-in-water cream bases containing 4% Ascorbyl Dipalmitate was studied using rabbits. Details relating to the test protocol and animals tested are not stated in this Korean publication abstract. The concentration of ascorbic acid in the urine varied depending on the characteristics of the cream bases that were tested. The absorption of ascorbic acid was increased and sustained with the cream bases containing branched chain esters of fatty acids instead of natural oils. The level of excretion of ascorbic acid in the urine was high for the cream base with nonionic surfactants and a small quantity of natural oils.

Human

Troxerutin (a flavonol drug), Ascorbyl Palmitate, and alpha-tocopheryl succinate were incorporated in 10 mg of a gel containing hydroxypropylcellulose, butylhydroxyltoluene and ethyl alcohol (95%). Alpha-tocopheryl succinate (100 mg) and Ascorbyl Palmitate (10 mg) were previously dissolved in ethyl alcohol, and troxerutin (30 mg) was previously dissolved in distilled water (0.8 ml). The gel (200 mg) was applied to a 25 cm² area of the forearm of 5 volunteers (2 women and 3 men) for 45 minutes. The stratum corneum was then removed using 12 strips of transparent adhesive tape. The experiment was repeated 3 times (on same forearm area), and each was carried out after a recovery period of 2 weeks. The gel (200 mg) served as the control, and was tested according to the same procedure. Test results indicated that, at 45 minutes post-application, Ascorbyl Palmitate and the 2 other substances had penetrated into the epidermis, and were found up to the tenth strip. Looking at the cumulated percentage of the 3 substances according to the strips, more than 80% of the total dose of troxerutin and alpha-tocopheryl succinate, and more than 90% of the total dose of Ascorbyl Palmitate was found.
Computational Analyses/Predictions

Ascorbyl Tetraisopalmitate

To simulate Ascorbyl Tetraisopalmitate absorption through human skin, Ascorbyl Tetraisopalmitate percutaneous absorption through the infundibulum (important route of absorption into the hair follicle of human skin) was modeled and compared with the stratum corneum membrane. This comparative study was performed via computer simulation by molecular dynamics (with Martini force field). The infundibulum membrane model was constructed according to the lipid composition of the human epidermis. The composition of the simulated infundibulum membrane was as follows: phosphatidylcholine (17%), phosphatidylserine (17%), phosphatidylethanolamine (18.8%), phosphatidylinositol (6.9%), sphingomyelin (9.8%), cholesterol (24.4%), cholesterol sulfate (1.5%), and ceramide type II (4.6%). The composition of the simulated stratum corneum membrane was: fatty acids with 24 carbons (39%), cholesterol (36%), and ceramide type II (25%).

A single Ascorbyl Tetraisopalmitate molecule penetrated the infundibulum membrane in approximately 320 nanoseconds (ns). In the case of 3 molecules, the first molecule penetrated in the first 10 ns and the other 2 molecules combined with each other and penetrated in 100 ns. When the number of Ascorbyl Tetraisopalmitate molecules was increased to 9, structural changes in the molecule due to clustering of groups was observed. Two molecules combined and penetrated the membrane together in the first 10 ns, 4 other molecules grouped together (~ 22 Ångstroms [Å]) and penetrated in 30 ns, and the last 3 molecules (~ 19 Å) penetrated in 110 ns. The authors noted that these structural changes were probably related to the solvent (water) and the hydrophobicity of Ascorbyl Tetraisopalmitate. Another observation was that the Ascorbyl Tetraisopalmitate molecules penetrated the first layer of the bilayer membrane and remained at that position for at least 1000 ns of simulation.

These data obtained for the infundibulum suggested that a high concentration of Ascorbyl Tetraisopalmitate molecule accelerated the process of penetration. The Ascorbyl tetraisopalmitate molecule was found to have more affinity toward the stratum corneum than toward the infundibulum, and a straight penetration pathway was observed for up to 600 ns of simulation. In the infundibulum, penetration followed a lateral pathway. The authors noted that the results of this study contribute to a better understanding of the different molecular interactions during the percutaneous absorption of active molecules in these two different types of biological membranes.

Penetration Enhancement

Ascorbyl Palmitate

Permeation tests of Ibuprofen (formulated in Ascorbyl Palmitate coagel (5% w/v) or ascorbyl laurate coagel (5% w/v), or suspended in isopropanol) through excised skin of hairless mice (Strain MF1- hr/hr/Ola, Nossan Srl, Correzzana, Milano) were performed using Franz-type cells. [At temperatures higher than the critical micellar temperature, 6-O-ascorbic acid alkanoate aqueous suspensions turn into either micellar solutions or gel phases, depending on the length of the hydrophobic chain. Upon cooling, coagels (liquid-crystal structures) are formed.] Results for the amount of ibuprofen in each vehicle that permeated (mg/cm² ± standard error of the mean) the skin after 20 h were: 2.10 ± 0.25 (in isopropanol), 0.83 ± 0.21 (in ascorbyl laurate), and 0.47 ± 0.05 (in Ascorbyl Palmitate).

Figure 1. Ibuprofen

Absorption, Distribution, Metabolism, and Excretion

In Vitro

Ascorbyl Palmitate and Ascorbyl Dipalmitate

The enzymatic hydrolysis of Ascorbyl Palmitate or Ascorbyl Dipalmitate was studied using guinea pig tissue homogenates (mixture of small intestine and pancreas homogenates). Details relating to the test protocol were not included.
in the Japanese publication abstract. The yields of ascorbic acid were 80% with Ascorbyl Palmitate and 20% with Ascorbyl Dipalmitate.

Animal

Oral

Ascorbyl Palmitate and Ascorbyl Dipalmitate

Ascorbyl Palmitate or Ascorbyl Dipalmitate (each equivalent to 20 mg ascorbic acid) was administered orally to guinea pigs (number per group not stated in Japanese publication abstract). The amounts of ascorbic acid in the urine, liver, adrenal gland, and blood plasma were determined. Urinary excretion was monitored for up to 48 h. Results were compared with those of a group of guinea pigs (number not stated) dosed orally with ascorbic acid. In the group dosed orally with ascorbic acid, the changes in ascorbic acid content of the organs over time were similar to those reported for the urine; however, a somewhat reverse finding was reported after oral dosing with Ascorbyl Palmitate or Ascorbyl Dipalmitate. In all 3 groups, the amount of ascorbic acid excreted in the urine in 0 to 24 h after dosing was greater than the amount excreted in 24 to 48 h.

Other Routes

Ascorbyl Palmitate

A study was performed to determine the occurrence of Ascorbyl Palmitate hydrolysis in brain tissue using 2 male Wistar rats. Ascorbyl Palmitate (in dimethylsulfoxide (DMSO)) was injected into an internal carotid artery at a dose of 75 mg per rat (dose volume = 0.3 ml). The animals were killed at 15 minutes post-injection, and the brain tissue was extracted with chloroform/methanol and chromatographed using thin-layer chromatography. Rf values (retention factors) were determined. The Rf value is used to quantify the movement of materials along the plate, and Rf is equal to the distance traveled by the substance divided by the distance traveled by the solvent.

Spots of Ascorbyl Palmitate were traceable in the hemispheres ipsilateral to the intracarotid Ascorbyl Palmitate injection side and in the contralateral hemispheres. The Rf factor of the spots corresponding to the brain samples of Ascorbyl Palmitate-injected rats was nearly identical to that of the standard spot. Rf was 0.465 for the Ascorbyl Palmitate standard, ipsilateral and contralateral samples in the first rat, and was 0.470 and 0.460 for the ipsilateral and contralateral samples, respectively, in the second rat. These results indicated that Ascorbyl Palmitate resisted hydrolysis in the rat brain, in that it penetrated the blood brain barrier and was retained principally in brain tissue as an intact molecule. No conclusion could be drawn as to the amount of Ascorbyl Palmitate that permeated through the blood brain barrier or the fraction that underwent hydrolysis in the brain. However, it was suggested that the extent of Ascorbyl Palmitate in the brain is rather minor in relation to the time span of 15 minutes between injection of the compound and the time that the animals were killed.

TOXICOLOGICAL STUDIES

Due to concerns about the safety of food additives, the EFSA established a program for the reevaluation of approved antioxidant food additives. The aim of this research was to predict the toxicity of antioxidant food additives using an in silico methodology for a preliminary evaluation of safety. The in silico prediction was conducted for the following endpoints: acute toxicity (LD50), genotoxicity, carcinogenicity, reproductive toxicity, chronic toxicity (no-observed-effect level (NOEL)), acceptable daily intake (ADI) value, and the toxicity of metabolites. The applied softwares used were Toxtree, TEST, Admet Predictor, and the OECD QSAR Toolbox. It was noted that many researchers perform a validation of the prediction methods used and compare methods of prediction between existing software to assess the accuracy and robustness of each platform. NOEL predictive values were calculated from the predicted value of the ADI, and these NOELs were used to predict long-term toxicity. The antioxidant metabolites were predicted by the method of Cytochrome P450. The in silico method predictions for Ascorbyl Palmitate and Ascorbyl Stearate appear in some of the toxicity sections included below, under the Computational Analyses/Predictions subheading.

Acute Toxicity Studies

Oral

Ascorbyl Tetraisopalmitate
The acute oral toxicity of an Ascorbyl Tetraisopalmitate trade name material was evaluated using Wistar rats of the Crl:(WI)BR strain (5 males, 5 females). A single oral dose (2000 mg/kg) of the test substance was administered by gavage to each animal. Dosing was followed by a 15-day observation period and necropsy. There were no clinical signs of toxicity and none of the animals died. Additionally, there was no evidence of organ toxicity at gross necropsy. The oral LD$_{50}$ was $>2000$ mg/kg.

**Computational Analyses/Predictions**

**Ascorbyl Palmitate**

Using an *in silico* methodology (mentioned at beginning of Toxicological Studies section), Ascorbyl Palmitate was predicted to be a moderately toxic compound.

**Ascorbyl Stearate**

Using an *in silico* methodology (mentioned at beginning of Toxicological Studies section), Ascorbyl Stearate was predicted not to be a slightly toxic compound.

**Chronic Toxicity Studies**

**Computational Analyses/Predictions**

**Ascorbyl Palmitate**

Using an *in silico* methodology (described at beginning of Toxicological Studies section), the NOEL for long-term toxicity of Ascorbyl Palmitate was calculated to be 916 mg/kg/day.

**Ascorbyl Stearate**

Using an *in silico* methodology (described at beginning of Toxicological Studies section), the NOEL for long-term toxicity of Ascorbyl Stearate was calculated to be 834 mg/kg/day.

**DEVELOPMENTAL AND REPRODUCTIVE TOXICITY STUDIES**

**Computational Analyses/Predictions**

**Ascorbyl Palmitate**

Using an *in silico* methodology (described at beginning of Toxicological Studies section), Ascorbyl Palmitate was predicted not to be a reproductive toxicant.

**Ascorbyl Stearate**

Using an *in silico* methodology (described at beginning of Toxicological Studies section), Ascorbyl Stearate was predicted not to be a reproductive toxicant.

**GENOTOXICITY STUDIES**

**In Vitro**

**Ascorbyl Tetraisopalmitate**

The genotoxicity of an Ascorbyl Tetraisopalmitate trade name material (in ethanol) was evaluated in the Ames test using *Salmonella typhimurium* and *Escherichia coli* bacterial strains (not stated) with and without metabolic activation. Doses of the test substance up to 1000 µg/plate were tested. The positive controls in this study were not stated. The test substance was non-genotoxic, with and without metabolic activation, over the range of doses tested. The negative and strain-
specific positive control values were within the background historical ranges associated with the laboratory where the test was performed.

**In Vivo**

**Computational Analyses/Predictions**

**Ascorbyl Palmitate**

Using an *in silico* methodology (described at beginning of Toxicological Studies section), Ascorbyl Palmitate was predicted to be a genotoxic compound.\(^4^1\)

**Ascorbyl Stearate**

Using an *in silico* methodology (described at beginning of Toxicological Studies section), Ascorbyl Stearate was predicted to be a non-genotoxic compound.\(^4^1\)

**CARCINOGENICITY STUDIES**

**Inhibition of Tumor Promotion**

**Dermal**

**Ascorbyl Palmitate**

The effect of Ascorbyl Palmitate (in acetone vehicle) on the induction of epidermal ornithine decarboxylase (ODC) activity, epidermal hyperplasia (epidermal thickness), skin edema, and skin tumor promotion by 1,8-dihydroxy-3-methyl-9-anthrone (chrysarobin, an anthrone tumor promoter) was tested using female SENCAR mice.\(^4^3\) The exact mechanism by which tumor promoters operate is unclear. However, many cellular and biochemical changes have been associated with tumor promoters and the process of tumor promotion, such as, sustained hyperplasia and the induction of ODC activity. For the analysis of edema and hyperplasia, groups of 4 mice were treated for 4 weeks (once weekly) with acetone, chrysarobin, or chrysarobin plus Ascorbyl Palmitate (4 µmol). After the final treatment with chrysarobin, the mice were killed at 24 h to measure edema, or, at 48 h, for histological analysis of hyperplasia. Ascorbyl Palmitate (4 µmol) inhibited (24% inhibition; \(p < 0.05\)) the induction of edema by chrysarobin (220 nmol). This dose of Ascorbyl Palmitate (4 µmol) also inhibited (26% inhibition; \(p < 0.05\)) the induction of epidermal hyperplasia by chrysarobin (220 nmol).

In the tumor induction experiment, groups of 30 mice were initiated with DMBA (25 nmol) and, 2 weeks later, received once weekly treatments of chrysarobin (220 nmol). Ascorbyl Palmitate (0.2 ml in acetone; 1 µmol, or 4 µmol doses) was applied to a shaved area of the back 5 minutes prior to the application of chrysarobin. The number and incidence of papillomas were recorded weekly. Promotion was continued until the average number of papillomas per mouse reached a plateau in all groups. Ascorbyl Palmitate inhibited chrysarobin-induced tumor promotion at concentrations of 1 µmol and 4 µmol, but the researchers noted that there was no good dose-related effect. At 27 weeks of promotion with chrysarobin (220 nmol per mouse), 1 µmol and 4 µmol Ascorbyl Palmitate reduced the average number of papillomas per mouse by 48% and 44%, respectively. Additionally, the number of papillomas per mouse in both groups receiving Ascorbyl Palmitate was significantly lower (\(p < 0.01\)) than the tumor response in the group that was promoted with chrysarobin alone.\(^4^3\)

An ODC assay was also performed in this study. Ascorbyl Palmitate was applied topically according to the procedure in the tumor induction experiment. At 60 h after chrysarobin application, mice were killed by cervical dislocation and the dorsal skin was surgically removed. Epidermal scrapings from groups of four mice were pooled, homogenized, and centrifuged. ODC activity in the soluble supernatant was determined by measuring the release of \(^1^4\)CO\(_2\) from L-(l-\(^1^4\)C) ornithine hydrochloride. When applied 5 minutes prior to treatment with chrysarobin (220 nmol), 1 µmol and 4 µmol Ascorbyl Palmitate inhibited the induction of ODC activity by 28% and 59%, respectively. Lower doses of Ascorbyl Palmitate (0.4 µmol) had little or no effect on chrysarobin-induced ODC activity.\(^5^3\)

The authors concluded that Ascorbyl Palmitate inhibited ODC activity, edema, epidermal hyperplasia, and skin tumor promotion induced by chrysarobin in this study.\(^4^3\)

**ANTI-CARCINOGENICITY STUDIES**

**Ascorbyl Palmitate**
A study was performed to determine whether derivatives of ascorbic acid increase tumor cell death, caused by hyperthermia, to further improve cancer treatment. Hyperthermia is a potent cancer treatment that inhibits the growth of tumor cells. The study was performed using human tongue squamous carcinoma cells (HSC-4). For the examination of carcinostatic activity, cells previously cultured for 24 h were suspended in culture medium. A test solution of Ascorbyl Palmitate (100 µM) was placed in a test tube and the solvent was evaporated by jet flow of nitrogen gas. Culture medium was then added to the residue and sonicated to become homogenously emulsified. The cell suspensions and test substance were mixed in a glass sample bottle. Hyperthermic treatment involved incubation of the cell suspension for 60 minutes at a temperature of 37°C or 42°C in a water bath. The suspension was then maintained by sequential culture for 24 h (at 37°C). Carcinostatic activity was evaluated using a crystal violet staining assay; cell morphology was observed under a phase-contrast microscope.

The cell viability of control cultures (at 37°C) was considered to be 100%, but was reduced to 57.3 ± 2.7% at 42°C (p < 0.0001). Treatment with Ascorbyl Palmitate at 37°C yielded a cell survival rate of 86.8 ± 5.7%. At 42°C, treatment with Ascorbyl Palmitate decreased cell viability to 42.0 ± 2.1% (p < 0.0001). The authors noted that the carcinostatic activity of Ascorbyl Palmitate was markedly increased with hyperthermia.

Ascorbyl Stearate

Human glioblastomas (gliomas) are characterized as highly invasive and rapidly growing brain tumors. A study was performed to determine the in vitro effect of Ascorbyl Stearate on cell proliferation, transformation, apoptosis and modulation of expression of insulin-like growth factor-I receptor (IGF-IR) in human glioblastoma multiforme (T98G) cells. Ascorbyl Stearate showed significant inhibition of fetal bovine serum and human recombinant insulin-like growth factor-I (IGF-I)-dependent cell proliferation in a dose-dependent manner. Treatment of T98G cells with 50, 100 and 150 μM Ascorbyl Stearate for 24 h slowed down the cell multiplication cycle, with significant accumulation of cells at the late S/G2-M phase of the cycle. Ascorbyl Stearate treatment (100 μM) reversed the transformed phenotype, as determined by clonogenicity in soft agar, and also induced apoptosis of T98G cells. These changes were said to have been associated with a significant decrease in IGF-IR expression in a dose- and time-dependent manner when compared to untreated controls. These data clearly demonstrated that Ascorbyl Stearate had antiproliferative and apoptotic effects on T98G cells, probably through modulation of IGF-IR expression and the facilitation of programmed cell death.

Pancreatic cancer is an aggressive tumor with short median survival, and is associated with a high mortality rate. A study was performed to evaluate the effects of Ascorbyl Stearate on pancreatic cancer. The treatment of human pancreatic carcinoma cells with Ascorbyl Stearate (50–200 µM) resulted in a dose-dependent inhibition of cell proliferation. Ascorbyl Stearate slowed down the cell cycle, accumulating human pancreatic carcinoma epithelial-like cells (PANC-1 cells) in late G2-M phase. Furthermore, Ascorbyl Stearate treatment (150 µM) markedly inhibited growth in soft agar and facilitated apoptosis of PANC-1 cells, but not human pancreatic ductal adenocarcinoma cells (Capan-2 cells). These effects were accompanied by a significant reduction in insulin-like growth factor 1 receptor (IGF1-R) expression, when compared to untreated controls. Capan-2 cells, the least responsive to Ascorbyl Stearate treatment, did not overexpress the IGF1-R. These results demonstrated the efficacy of Ascorbyl Stearate in inhibiting the growth of pancreatic cancer cells.

The effect of Ascorbyl Stearate (25 to 150 µM) on human ovarian epithelial cancer cells (OVCAR-3 cells) was studied. Treatment with Ascorbyl Stearate caused a dose-dependent inhibition of cell proliferation. The antiproliferative effect was due to the arrest of cells in the S/G2-M-phase of the cell cycle. Treatment of OVCAR-3 cells with Ascorbyl Stearate also inhibited phosphatidylinositol-3-kinase and protein kinase B (PI3K/AKT) activity. The presence of a constitutively active AKT protected OVCAR-3 cells from the effects of Ascorbyl Stearate, suggesting that this ester targets the PI3K/AKT pathway. The administration of Ascorbyl Stearate by gavage induced involution of human ovarian carcinoma xenografts in nude mice. These studies indicate that the antiproliferative effect of Ascorbyl Stearate on ovarian epithelial cancer cells is associated with decreased PI3K/AKT activity, and point toward the PI3K/AKT signaling pathway as a target for this drug. Data from another study indicated that the anti-proliferative activity of Ascorbyl Stearate on ovarian cancer cells was due in part to G2/M (G2/M phase of the cell cycle) arrest modulated by means of a tumor protein p53-dependent pathway.

OTHER RELEVANT STUDIES

Promotion of Lipid Peroxidation

Ascorbyl Palmitate

A study was performed to determine the antioxidative properties of Ascorbyl Palmitate using human keratinocyte cultures. The fatty acid analog cis-parinaric acid (cPA) was used to quantify lipid peroxidation. This fluorescent fatty acid
analog integrates into membranes, where it is readily oxidized because of its extensive unsaturation. As oxidized cPA loses fluorescence, relative levels of lipid peroxidation can be determined. Keratinocytes treated with 10 to 100 µM Ascorbyl Palmitate prior to UVB irradiation showed increased loss of fluorescence. At the 100 mM dose, there was significant loss of cPA fluorescence, versus UVB-irradiated cells not exposed to Ascorbyl Palmitate ($p < 0.05$), with little residual fluorescence detectable. UVB-induced increases in lipid peroxidation in the absence of Ascorbyl Palmitate were readily detected ($p < 0.05$ versus nonirradiated cells). Cells pretreated with 100 or 300 mM Ascorbyl Palmitate for 30 minutes prior to irradiation showed dose-dependent increases in mean fluorescence values. At the 300 mM dose, Ascorbyl Palmitate pretreatment resulted in significant increases in lipid peroxidation when compared to UVB irradiation only (no Ascorbyl Palmitate).

Levels of reactive oxygen species were determined using the fluorescent probe dihydrorhodamine (DHR). Keratinocytes were loaded with DHR, pretreated with 1 to 25 µM Ascorbyl Palmitate, and exposed to UVB. Ascorbyl Palmitate effectively inhibited DHR oxidation in a dose-dependent manner, indicating its antioxidant potential. Thus, Ascorbyl Palmitate reduced cellular levels of reactive oxygen species after UVB irradiation.

Furthermore, the treatment of keratinocytes with Ascorbyl Palmitate inhibited UVB-mediated activation of epidermal growth factor receptor, extracellular regulated kinases 1 and 2, and p38 kinase because of its ability to prevent reduced glutathione depletion and scaveng hydrogen peroxide. However, Ascorbyl Palmitate strongly promoted UVB-induced lipid peroxidation, c-Jun N-terminal kinase activation, and cytotoxicity. The authors noted that the lipid component of Ascorbyl Palmitate probably contributes to the generation of oxidized lipid metabolites that are toxic to epidermal cells. They also noted that the data in this study suggest that, despite its antioxidant properties, Ascorbyl Palmitate may intensify skin damage following physiologic doses of UV radiation.

**DERMAL IRRITATION AND SENSITZATION STUDIES**

**Irritation**

**Animal**

**Ascorbyl Tetraisopalmitate**

The skin irritation potential of an Ascorbyl Tetraisopalmitate trade name material was evaluated according to OECD Guideline 404 using 3 New Zealand white rabbits. The test substance (0.5 ml, no vehicle) was applied for 4 h, under a semicocclusive patch, to a 10 x 15 cm² area of skin on one flank. Following application, the animals were observed for up to 72 h. Any evidence of skin irritation (reactions not specified) was fully reversible within 2 days. Effects other than irritation were not observed. The test substance was classified as a non-irritant (primary irritation index (PII) = 0.3, classified as negligibly irritating).

**Sensitization**

**Animal**

**Ascorbyl Tetraisopalmitate**

The guinea pig maximization test was used to evaluate the skin sensitization potential of an Ascorbyl Tetraisopalmitate trade name material. The test substance (undiluted) was applied to 10 guinea pigs during induction (epidermal application and intradermal injection) and the challenge phase (epidermal application). Five guinea pigs served as negative controls (substance applied not stated). Following intradermal injection (0.1 ml into scapular region), reactions were assessed 24 h and 48 h later. For the epidermal application, a 2 x 3 cm non-woven patch containing 0.5 ml of the test substance, secured with an elastic bandage, was applied for 24 h to the flank. Again, reactions were assessed at 24 h and 48 h post-administration. There was no evidence of irritation during the induction phase. Skin sensitization was observed in 8 of 10 animals, but not in any of the 5 negative control animals. Scaling (at application site) was observed in one animal. The skin sensitization rate was 80%, and the test substance was considered to have strong sensitization properties.

**Human**

**Ascorbyl Tetraisopalmitate**

The skin sensitization potential of an Ascorbyl Tetraisopalmitate trade name material was evaluated in a human repeated insult patch test (HRRIPT) involving 102 male and female subjects. The duration of the induction phase was 3 consecutive weeks. A 20 x 20 mm occlusive patch containing the test substance (10% dilution in silicone; 0.2 ml) was
applied to the skin (site not stated) for a total of nine 24-h induction applications. The induction phase was followed by a 10- to 14-day non-treatment period. During the challenge phase, the test substance was applied for 24 h to a previously untreated site. Reactions were scored at 24 h and 48 h post-application. No adverse reaction of any kind was observed during the study. It was concluded that Ascorbyl Tetraisopalmitate (10% dilution in silicone) was not a skin sensitizer in this study.

CLINICAL STUDIES

Case Reports

Ascorbyl Tetraisopalmitate

A 54-year-old non-atopic woman presented with a skin reaction 2 days after the initial application of an anti-aging skin care product. The reaction began on the face, and spread to the arms and pre-sternum. Patch testing with ingredients from various test series was performed using patch test chambers, and reactions were scored according to the guidelines of the International Contact Dermatitis Research Group (ICDRG) on days 2, 4, and 7. The patient had positive patch test reactions to methylchlorothiazolinone (100 ppm), thiomersal, and the product. The results of a repeated open application test (ROAT) with the product became positive after 3 days. Patch testing with the ingredients of the product revealed a strong positive reaction to Ascorbyl Tetraisopalmitate (20% in liquid paraffin); negative results were reported for the 20 control subjects patch tested with this ingredient.

An 83-year-old man was treated for atopic dermatitis with a non-steroidal over-the-counter (OTC) moisturizer that contained Ascorbyl Tetraisopalmitate. Acute contact dermatitis that spread rapidly to the limbs and trunk was observed on application day 14. Patch tests (chambers) were performed according to ICDRG guidelines; reactions were scored on days 2 and 4. Patch test results for Ascorbyl Tetraisopalmitate (0.05%; dose/cm² not stated) were positive (++ reaction) on day 4. The patient refused any additional investigation.

Other Clinical Reports

Tetrahexyldecyl Ascorbate

Ten patients applied, in a double-blind manner, a newly formulated vitamin C complex containing 10% ascorbic acid (water soluble) and 7% Tetrahexyldecyl Ascorbate (lipid soluble) in an anhydrous polysilicone gel base to one-half of the face. Inactive polysilicone gel base was applied to the opposite side. Clinical evaluation of inflammation was performed prior to the study and at weeks 4, 8, and 12. Biopsies of both sides of the face, sampling a treated area as well as a control area, were performed at week 12 in four patients. Inflammation of the skin was assessed as present or absent, and the presence or absence of an inflammatory infiltrate in biopsy specimens was evaluated as well. No patients were found to have either clinical or histologic evidence of inflammation on either side of the face. The average epidermal thickness of the treatment side was 51.8 µm, while that of the gel-base side was 48.1 µm. The Grenz zone collagen measurements averaged 52.5 µm on the gel-base side and 35.5 µm on the gel-base side, indicating new collagen formation. There was one patient that showed no difference in epidermal thickness between the treatment and gel-base sides, while three patients showed an increase on the treatment side.

A clinical trial on a moisturizer was performed using 37 female subjects. The composition of the moisturizer was as follows: Astragalus membranaceus root extract, a peptide blend including palmitoyl tripeptide-38, standardized rosemary leaf extract (ursolic acid), ubiquinone (coenzyme Q10), and Tetrahexyldecyl Ascorbate. The subjects were instructed to apply the moisturizer twice per day, and were evaluated at baseline and after 4, 8, and 12 weeks of product use. A vehicle control was not used in the study. Digital photography was used to document changes in appearance. At weeks 8 and 12, statistically significant (p < 0.001) improvement in the following parameters was reported: fine lines, wrinkles, clarity/brightness, visual roughness, tactile roughness, evenness of skin tone (redness), evenness of skin tone (hyperpigmentation), and overall appearance. Levels of improvement for the parameters evaluated ranged from 89% to 100%, with most of the improvement in the 97% to 100% range. The moisturizer was well-tolerated by the panelists, i.e., there was no statistically significant increase in scores for tolerability parameters at all time points, when compared to baseline scores. Details relating to the tolerability parameters evaluated were not included.

A single-center study was performed in order to assess the efficacy and tolerance of a dual-product regimen containing a 0.5% retinol treatment and an anti-aging moisturizer containing 30% Tetrahexyldecyl Ascorbate. In addition to encapsulated retinol, the 0.5% retinol treatment contained bakuchiol and Ophiopogon japonicas root extract. In addition to 30% Tetrahexyldecyl Ascorbate, the anti-aging moisturizer also contained vitamin E and coenzyme Q10. The dual-product
regimen was used over a 12-week period by 44 women who had mild-to-moderate facial hyperpigmentation and photodamage. At the baseline visit, the subjects were instructed to apply the anti-aging moisturizer to the entire face once per day in the morning after cleansing. For the first 2 weeks of the study, the subjects were instructed to apply the 0.5% retinol treatment to the entire face every other evening. After the 2-week period, the subjects were instructed to apply the retinol treatment every evening. Tolerability parameters were assessed, at baseline and weeks 4, 8, and 12, and included: erythema, dryness, scaling, burning, stinging, and itching. Use of the dual-product regimen resulted in a statistically significant increase (worsening) in clinical grading scores for dryness on the face at weeks 4 (15% of the subjects) and 8 (13% of the subjects) when compared to baseline scores. However, this change did not persist to the week 12 time point. No statistically significant changes from baseline were detected for the following at weeks 4, 8, and 12: erythema, scaling, burning, stinging, or itching.

A clinical test was performed to clarify the effect of Tetrahexyldecyl Ascorbate on UVB-induced skin pigmentation. Twenty-two males and females with characteristic Japanese photo-skin type II or III were enrolled in the study. The inner side of the upper arm was used for testing as the site of sun-protected skin. The subjects were exposed to 1.5 MED of solar-simulated light. Following exposure, a cream containing 3% Tetraisopalmitoyl Ascorbic Acid or vehicle only (oil-in-water type cream) was topically applied to the UV-irradiated area immediately after irradiation. After 1, 2 and 3 weeks, intensities of pigmentation were evaluated with L* value (parameter for lightness of skin; measured with chromameter) measurement. Based on visual scoring, statistically significant differences between vehicle-treated areas and Tetraisopalmitoyl Ascorbic Acid-treated areas were reported 1 week after UVB irradiation (p < 0.05). ΔL*-values (L* of each week - L* before UV-irradiation) of Tetraisopalmitoyl Ascorbic Acid-treated areas were significantly lower than those of vehicle-treated areas at 1 week and at 2 weeks after UVB irradiation (p < 0.05). It was concluded that the topical application of a 3% Tetraisopalmitoyl Ascorbic Acid cream suppressed pigmentation after UVB irradiation.

**Ascorbyl Palmitate**

Ascorbyl Palmitate was applied to the skin, damaged by ultraviolet radiation, of 5 subjects. In the first experiment, areas of the skin (forearm) were either left unprotected or had been treated topically with 3% Ascorbyl Palmitate (in a lecithin gel base) prior to UVB exposure (1 to 3 times the minimal erythema dose (MED). When compared to untreated skin, either the absence of erythema or decreased erythema was observed after pretreatment with 3% Ascorbyl Palmitate before UVB exposure. In the second experiment, erythema was produced by UVB exposure in the range of 1 to 2 times the MED and the skin was treated topically with a 5% Ascorbyl Palmitate lotion 3 h later. When compared to untreated skin, the UVB-induced erythema resolved approximately 50% sooner in skin treated with the lotion.

**SUMMARY**

The safety of the following 7 ingredients, alkylated or acylated derivatives of ascorbic acid, in cosmetics is being evaluated in this safety assessment: Tetrahexyldecyl Ascorbate, Ascorbyl Isostearate, Ascorbyl Linoleate, Ascorbyl Tetraisostearate, Ascorbyl Palmitate, Ascorbyl Dipalmitate, and Ascorbyl Stearate. The functions of these ingredients in cosmetic products include: antioxidants; skin-conditioning agents; skin protectants; fragrance ingredients; and skin bleaching agents. Ascorbyl Palmitate is the only ingredient with an additional function of fragrance ingredient, and Ascorbyl Linoleate is the only ingredient with an additional function of skin bleaching agent; however, functioning as a skin bleaching agent is not a cosmetic use and, therefore, the Panel did not evaluate safety for that use.

According to the 2016 VCRP data, the greatest reported use frequency is for Tetrahexyldecyl Ascorbate (397 formulations, mostly leave-on products). A cosmetics industry survey of ingredient use concentrations is being conducted.

Skin penetration data from in vitro studies indicated that Ascorbyl Palmitate was delivered mainly to the epidermis, but was not found in the receptor fluid. Ascorbic acid levels in pig skin were not significantly increased after Ascorbyl Palmitate was applied to skin positioned in a semi-occlusive chamber. In an in vivo percutaneous absorption study involving rabbits, 6 different oil-in-water cream bases containing 4% Ascorbyl Dipalmitate were applied to the skin. The concentration of ascorbic acid in the urine varied depending on the characteristics of the cream bases that were tested.

Ascorbyl Palmitate (10 mg in ethyl alcohol) penetrated into the epidermis after dermal application to human subjects. When the absorption of Ascorbyl Tetraisopalmiate through human skin was simulated using stratum corneum and infundibulum membrane models, the Ascorbyl Tetraisopalmiate molecule was found to have more affinity toward the stratum corneum than toward the infundibulum.

In a skin penetration enhancement study, the amount of ibuprofen that penetrated the skin after 20 h was dependent upon the vehicle that was used. Values for ibuprofen in isopropanol and Ascorbyl Palmitate vehicles were 2.10 ± 0.25 mg/cm² and 0.47 ± 0.05 mg/cm², respectively.
Ascorbic acid was detected in the urine of guinea pigs at 24 h after oral dosing with Ascorbly Palmitate or Ascorbly Dipalmitate. Ascorbly Palmitate resisted hydrolysis in the brain of rabbits after injection into the internal carotid artery. It penetrated the blood brain barrier and was retained principally in brain tissue as an intact molecule.

An acute oral LD₅₀ of > 2000 mg/kg was reported in a study involving rats. There were no clinical signs of toxicity, and none of the animals died. Using in silico methodology, Ascorbly Palmitate and Ascorbly Stearate were predicted to be moderately toxic and slightly toxic compounds, respectively.

Using in silico methodology, the NOEL for long-term toxicity was calculated to be 916 mg/kg/day for Ascorbly Palmitate and 834 mg/kg/day for Ascorbly Stearate.

Ascorbly Palmitate and Ascorbly Stearate were not predicted to be reproductive toxicants using in silico methodology.

Ascorbly Tetraisopalmitate was non-genotoxic in the Ames test, with and without metabolic activation. Using in silico methodology, Ascorbly Palmitate was predicted to be a genotoxic compound, whereas Ascorbly Stearate was not predicted to be a genotoxic compound.

Ascorbly Palmitate (1 µmol and 4 µmol) inhibited chrysarobin-induced tumor promotion in female SENCAR mice, but the authors noted that there was no good dose-related effect. At concentrations of 1 µmol and 4 µmol, Ascorbly Palmitate reduced the average number of papillomas per mouse by 48% and 44%, respectively. Furthermore, the number of papillomas per mouse in both groups of 30 mice treated with Ascorbly Palmitate was significantly lower (p < 0.01) than the tumor response in the group that was promoted with chrysarobin alone.

The treatment of HSC-4 cultures with Ascorbly Palmitate (100 µM) at 37°C yielded a cell survival rate of 86.8 ± 5.7%. At 42°C, cell viability decreased to 42.0 ± 2.1% (p < 0.0001). Thus, the carcinostatic activity of Ascorbly Palmitate was markedly increased with hyperthermia. Ascorbly Stearate (doses up to 150 µM) had antiproliferative and apoptotic effects on T98G cells, probably through modulation of IGF-IR expression and the facilitation of programmed cell death. The treatment of human pancreatic carcinoma cells with Ascorbly Stearate (50 - 200 µM) resulted in a dose-dependent inhibition of cell proliferation. Ascorbly Stearate (25 to 150 µM) also caused a dose-dependent inhibition of cell proliferation in human ovarian epithelial cancer cells.

The pretreatment of human keratinocytes with Ascorbly Palmitate (300 mM) prior to UVB irradiation resulted in significant increases in lipid peroxidation, when compared to UVB irradiation only. In another experiment in the same study, human keratinocytes were loaded with DHR, pretreated with 1 to 25 µM Ascorbly Palmitate, and exposed to UVB. Ascorbly Palmitate effectively inhibited DHR oxidation in a dose-dependent manner, which was indicative of its antioxidant potential. Ascorbly Palmitate reduced cellular levels of reactive oxygen species after UVB irradiation. Ascorbly Palmitate also strongly promoted UVB-induced lipid peroxidation, c-Jun N-terminal kinase activation, and cytotoxicity. It was noted noted that the lipid component of Ascorbly Palmitate probably contributes to the generation of oxidized lipid metabolites that are toxic to epidermal cells.

An Ascorbly Tetraisopalmitate trade name material (0.5 ml) was non-irritating to the skin of 3 rabbits. In the maximization test, application of the same material (undiluted) to the skin of 10 guinea pigs resulted in strong sensitization (skin sensitization rate of 80%). In an HRIPT involving 102 subjects, the same trade name material (10% in silicone) was not a skin sensitizer.

In a study involving 5 human subjects, either the absence of erythema or decreased erythema, compared to untreated skin, was observed after pretreatment with 3% Ascorbly Palmitate before UVB exposure. When the same subjects were exposed to UVB, followed by topical treatment with 5% Ascorbly Palmitate lotion, the UVB-induced erythema resolved approximately 50% sooner when compared to untreated skin.

When a newly formulated vitamin C complex containing 10% ascorbic acid and 7% Tetrahexyldecyl Ascorbate was applied to the face of 10 patients for 12 weeks, there was neither clinical nor histologic evidence of inflammation; however, there was evidence of new collagen formation. In a clinical trial involving 37 subjects, a moisturizer containing Tetrahexyldecyl Ascorbate (concentration not stated) was said to have been well-tolerated. The moisturizer was applied twice per day for 12 weeks.

A single-center study involving 44 subjects was performed to assess the efficacy and tolerance of a moisturizer containing 30% Teterahexyldecyl Ascorbate. The product was applied over a 12-week period. No statistically significant changes from baseline were detected for the following tolerability parameters: erythema, scaling, burning, stinging, or
itching. A clinical test involving 22 subjects was performed to clarify the effect of a cream containing 3% Tetrahexyldecyl Ascorbate on UVB-induced skin pigmentation. The cream was applied following UVB irradiation. Pigmentation intensity was evaluated for up to 3 weeks post-application. It was concluded that topical application of the cream after UVB irradiation resulted in the suppression of pigmentation.

Table 1. Data from CIR Final Safety Assessment on Esters of Ascorbic Acid.

<table>
<thead>
<tr>
<th>Test Substance</th>
<th>Animals/Subjects/ Tissues/Cells Studied</th>
<th>Procedure</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ascorbyl Palmitate</td>
<td>Guinea pigs</td>
<td>Topical application</td>
<td>Skin penetration of Ascorbyl Palmitate. Ascorbic acid content in skin, liver, and blood increased 8-, 7-, and 4-fold when compared to control animals.</td>
</tr>
<tr>
<td>$^{14}$C-Ascorbyl Palmitate</td>
<td>Guinea pigs with scurvy</td>
<td>Topical application</td>
<td>Ascorbic acid concentrations in the skin, liver, kidneys, and blood were 4 to 8 times greater when compared to control.</td>
</tr>
</tbody>
</table>

Absorption, Distribution, Metabolism, and Excretion – Oral Studies

<table>
<thead>
<tr>
<th>Test Substance</th>
<th>Animals/Tissues/Cells Studied</th>
<th>Procedure</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ascorbyl Palmitate (dissolved in sodium taurocholate solution)</td>
<td>Guinea pigs</td>
<td>Oral dosing</td>
<td>Hydrolysis by homogenates of the liver, pancreas, and intestines. ~80% of Ascorbyl Palmitate hydrolyzed to free ascorbic acid in small intestines and pancreas.</td>
</tr>
<tr>
<td>Ascorbyl Palmitate (the equivalent of 20 mg ascorbic acid)</td>
<td>Guinea pigs</td>
<td>Oral dosing</td>
<td>Greater amounts of ascorbic acid excreted at 0 to 24 h than at 24 to 48 h.</td>
</tr>
<tr>
<td>Ascorbyl Dipalmitate (~20% in sodium taurocholate solution)</td>
<td>Guinea pigs</td>
<td>Oral dosing</td>
<td>Hydrolyzed to free ascorbic acid by homogenates of small intestines and pancreas.</td>
</tr>
<tr>
<td>Ascorbyl Dipalmitate (the equivalent of 20 mg ascorbic acid)</td>
<td>Guinea pigs</td>
<td>Oral dosing</td>
<td>Greater amounts of ascorbic acid excreted at 0 to 24 h than at 24 to 48 h. Difference in body retention or availability of Ascorbyl Palmitate and Ascorbyl Dipalmitate found, due to differences in extent and rate of hydrolysis of the 2 esters.</td>
</tr>
</tbody>
</table>

Acute Toxicity – Oral Studies

<table>
<thead>
<tr>
<th>Test Substance</th>
<th>Animals/Tissues/Cells Studied</th>
<th>Procedure</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ascorbyl Palmitate (33.3% suspension)</td>
<td>Rats</td>
<td>Oral dosing</td>
<td>Lowest effect level = 2500 mg/kg/day.</td>
</tr>
<tr>
<td>Ascorbyl Palmitate (15% suspension)</td>
<td>Rats</td>
<td>Oral dosing</td>
<td>LD₅₀ = 5 g/kg.</td>
</tr>
<tr>
<td>Ascorbyl Dipalmitate</td>
<td>Mice</td>
<td>Oral dosing</td>
<td>LD₅₀ = 2 g/kg.</td>
</tr>
<tr>
<td>Ascorbyl Stearate</td>
<td>Rats</td>
<td>Oral dosing</td>
<td>No adverse effects in rats fed 100 to 3000 mg/kg.</td>
</tr>
</tbody>
</table>

Short-term Toxicity – Oral Study

<table>
<thead>
<tr>
<th>Test Substance</th>
<th>Animals/Tissues/Cells Studied</th>
<th>Procedure</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ascorbyl Palmitate</td>
<td>Female mice</td>
<td>Feeding for 63 days.</td>
<td>No signs of toxicity at doses up to 3000 mg/kg/day.</td>
</tr>
</tbody>
</table>

Chronic Toxicity – Oral Studies
# Table 1. Data from CIR Final Safety Assessment on Esters of Ascorbic Acid.²

<table>
<thead>
<tr>
<th>Test Substance</th>
<th>Animals/Subjects/Tissues/Cells Studied</th>
<th>Procedure</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ascorbyl Palmitate (0.25% in diet)</td>
<td>Rats</td>
<td>Feeding with doses ≥ 2500 mg/kg/day for 728 days</td>
<td>No toxic effects at 125 or 1000 mg/kg/day. Decreased body weight at doses of 2500 mg/kg/day and above. Oxalate stones in 2 of 8 rats dosed with 2500 mg/kg/day.⁶⁷</td>
</tr>
</tbody>
</table>

## Chronic Toxicity – Oral Studies

| Ascorbyl Palmitate (2% and 5% in feed) | Rats (10 per group) | Feeding in diet for 9 months | Significant growth retardation at 5% in diet; 2 of 10 rats with bladder stones and hyperplasia of bladder epithelium and 1 rat with nephritis. Slight growth retardation in 2% dietary group.⁶ |
| Ascorbyl Palmitate (2% or 5% in heat-treated lard diet). 2% or 5% Ascorbyl Palmitate (equivalent to 424 mg/kg and 1060 mg/kg, or 0.05% and 0.25% of total diet) | Rats (8 per group) | 2-year feeding study | Decreased growth rate at higher dose; 2 of 8 rats with oxalate stones after feeding for 9 months.⁶ |

## Genotoxicity

| Ascorbyl Palmitate | Salmonella typhimurium strains TA1535, TA1537, and TA1538 | Ames test. Ascorbyl Palmitate (was dissolved in 0.067 M potassium or sodium sulfate buffer at pH 7) tested at doses of 0.01 to 3.3 mg/plate. Doses > 3.3 mg/plate toxic to bacteria. | Non-genotoxic.⁶⁸ |
| Ascorbyl Palmitate | Escherichia coli strain WP2 | Tryptophan reversion assay. Ascorbyl Palmitate (was dissolved in 0.067 M potassium or sodium sulfate buffer at pH 7) tested at doses of 0.01 to 3.3 mg/plate. | Non-genotoxic.⁶⁸ |

## Carcinogenicity – Oral Studies

| Ascorbyl Palmitate (2% in diet) | Female CF-1 mice (groups of 12) | Mice (6/group) fed test or control diet for 2 weeks. Remaining 6 mice of one group injected subcutaneously (s.c.) with 10 mg/kg azoxymethanol (induces focal areas of dysplasia [FADs]) in saline once weekly for 6 weeks. 6 mice of the other group injected with saline (same procedure). | Ascorbyl Pamitate was nontoxic. S.c. administration of azoxymethanol induced proliferation of colonic epithelial cells and the expansion of the proliferative compartment, as well as formation of FADs. No FADs in control mice or those fed Ascorbyl Palmitate. Feeding also did not inhibit proliferation of or reduce number of induced FADs.⁶⁶ |

## Co-Carcinogenicity – Oral Study

| Ascorbyl Dipalmitate or Ascorbyl Stearate (5% in basal diet) | F344 male rats | Rats initiated with N-butyl-(4-hydroxybutyl)nitrosamine (BBN) and administered 5% Ascorbyl Dipalmitate or 5% Ascorbyl Stearate | No lesions of the liver or kidneys in rats of test or control group.⁶⁰ |

## Anti-Carcinogenicity – Dermal Study

| Ascorbyl Palmitate (4 or 5 µmol) | Mice and mouse epithelial cells | Topical application of small doses (4 or 5 µmol). Ascorbyl Palmitate (5 µmol) | Topical application caused inhibition of 12-O-
<table>
<thead>
<tr>
<th>Test Substance</th>
<th>Animals/Subjects/Tissues/Cells Studied</th>
<th>Procedure</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ascorbyl Palmitate (0.017 mmol)</td>
<td>Mice</td>
<td>Subcutaneous injection</td>
<td>Inhibited growth of sarcoma 180 in mice.(^7)</td>
</tr>
<tr>
<td><strong>Dermal Irritation</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ascorbyl Palmitate (10% aqueous)</td>
<td>Albino rabbits</td>
<td>Modified Draize test: 24-h occlusive patches</td>
<td>Non-irritating to intact, shaved skin.(^6)</td>
</tr>
<tr>
<td>Ascorbyl Dipalmitate (undiluted)</td>
<td>Albino rabbits</td>
<td>Modified Draize test: 24-h occlusive patches</td>
<td>Non-irritating to intact, shaved skin.(^6)</td>
</tr>
<tr>
<td><strong>Dermal Sensitization</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ascorbyl Palmitate (0.2% in eye cream)</td>
<td>26 male and female subjects</td>
<td>Maximation test. 0.1 ml applied (48 h, to arm, forearm, or back) under occlusive patches during induction (5 applications total). Challenge reactions at new site scored at 48 h and 72 h.</td>
<td>No adverse reactions or signs of sensitization.(^7)</td>
</tr>
<tr>
<td>Ascorbyl Palmitate (1%, 3%, and 5% in petrolatum)</td>
<td>106 subjects</td>
<td>Modified Draize assay. 10 induction applications, under occlusive patches (in Finn chamber), to scapular back. 48-h challenge patch applied to new site. Reactions scored at 96 h.</td>
<td>Seven 1+ reactions (1% concentration) in one subject; five 1+ reactions (5% concentration) in one subject. No reactions to 3% concentration. Ascorbyl palmitate classified as non-sensitizing at concentrations of 1% to 5%.(^7)</td>
</tr>
<tr>
<td><strong>Phototoxicity</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ascorbic Acid (10%)</td>
<td>Pigs</td>
<td>Topical application</td>
<td>Treated skin protected from UVB damage (as measured by erythema and sunburn cell formation) and UVA-mediated phototoxic reactions. Number of sunburn cells reduced by 42% when compared to controls (20% propylene glycol (v/v) with 0.5% hydroxypropylcellulose).(^7)</td>
</tr>
<tr>
<td><strong>Ocular Irritation</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ascorbyl Palmitate (10% aqueous)</td>
<td>Albino rabbits</td>
<td>Modified Draize test. Instilled (0.1 ml) into conjunctival sac</td>
<td>Non-irritating.(^6)</td>
</tr>
<tr>
<td>Ascorbyl Dipalmitate (undiluted)</td>
<td>Albino rabbits</td>
<td>Modified Draize test. Instilled (0.1 ml) into conjunctival sac</td>
<td>Minimally irritating.(^6)</td>
</tr>
<tr>
<td>Ingredient CAS No.</td>
<td>Definition &amp; Structure</td>
<td>Function</td>
<td></td>
</tr>
<tr>
<td>-------------------</td>
<td>------------------------</td>
<td>----------</td>
<td></td>
</tr>
<tr>
<td>Tetrahexyldecyl Ascorbate 1445760-15-5</td>
<td>Tetrahexyldecyl Ascorbate is the organic compound that conforms to the formula:</td>
<td>Antioxidants; Skin-Conditioning Agents - Miscellaneous</td>
<td></td>
</tr>
<tr>
<td>Ascorbyl Tetraisopalmitate 161436-56-2 183476-82-6</td>
<td>Ascorbyl Tetraisopalmitate is the tetraester of Ascorbic Acid and isopalmitic acid. It conforms generally to the formula:</td>
<td>Antioxidants; Skin-Conditioning Agents - Emollient</td>
<td></td>
</tr>
<tr>
<td>Ascorbyl Dipalmitate 28474-90-0</td>
<td>Ascorbyl Dipalmitate is the diester of Ascorbic Acid and palmitic acid. It conforms generally to the formula:</td>
<td>Antioxidants</td>
<td></td>
</tr>
<tr>
<td>Ingredient</td>
<td>CAS No.</td>
<td>Definition &amp; Structure</td>
<td>Function</td>
</tr>
<tr>
<td>--------------------</td>
<td>----------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Ascorbyl Isostearate</td>
<td></td>
<td>Ascorbyl Isostearate is the ester of Ascorbic Acid and isostearic acid. It conforms generally to the formula:</td>
<td>Skin-Conditioning Agents - Miscellaneous</td>
</tr>
<tr>
<td>Ascorbyl Linoleate</td>
<td>121869-32-7</td>
<td>Ascorbyl Linoleate is the organic compound that conforms to the formula:</td>
<td>Antioxidants; Skin Bleaching Agents; Skin Protectants; Skin-Conditioning Agents - Miscellaneous</td>
</tr>
<tr>
<td>Ascorbyl Palmitate</td>
<td>137-66-6</td>
<td>Ascorbyl Palmitate is the ester of Ascorbic Acid and palmitic acid. It conforms generally to the formula:</td>
<td>Antioxidants; Fragrance Ingredients</td>
</tr>
<tr>
<td>Ascorbyl Stearate</td>
<td>25395-66-8</td>
<td>Ascorbyl Stearate is the ester of Ascorbic Acid and stearic acid. It conforms generally to the formula:</td>
<td>Antioxidants</td>
</tr>
<tr>
<td>Property</td>
<td>Value</td>
<td>Background Information</td>
<td></td>
</tr>
<tr>
<td>--------------------------------</td>
<td>--------------------------------</td>
<td>-----------------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td><strong>Form</strong> (at 20°C and 1013 hPa)</td>
<td>Liquid.42</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Color</strong> (at 20°C and 1013 hPa)</td>
<td>Colorless to light yellow.42</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Melting Point (°C)</td>
<td>-61 to 60.42</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decomposition (°C)</td>
<td>~ 164.42</td>
<td>No boiling was observed below the decomposition temperature.42</td>
<td></td>
</tr>
<tr>
<td>Density (g/cm³ at 20°C)</td>
<td>0.94.42</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vapor Pressure (Pa at 20°C)</td>
<td>&lt;0.42</td>
<td></td>
<td></td>
</tr>
<tr>
<td>log P_{ow} (at 24°C)</td>
<td>&gt;6.2.42</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Water Solubility (at 95°C and pH ~7.5)</td>
<td>&lt;0.09 mg/l.42</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Ascorbyl Palmitate</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Form</td>
<td>White or yellowish-white powder.2</td>
<td>Appearance at room temperature.2</td>
<td></td>
</tr>
<tr>
<td>Molecular Weight</td>
<td>414.54.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Odor</td>
<td>Citrus-like.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Solubility</td>
<td>Soluble in alcohol and vegetable oils; slightly soluble in water.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Melting Point (°C)</td>
<td>107-117°C.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Ascorbyl Stearate</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Form</td>
<td>White crystalline powder.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Melting Point (°C)</td>
<td>115-118°C.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Tetrahexyldecyl Ascorbate</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Form</td>
<td>Clear, colorless liquid.49</td>
<td>Thermally stable, without change from colorless.</td>
<td></td>
</tr>
<tr>
<td>Density</td>
<td>0.93.49</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Viscosity (cPs, at 20°C)</td>
<td>280.49</td>
<td>Almost soluble in oily materials.49</td>
<td></td>
</tr>
<tr>
<td>Solubility</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 4. Current Frequency and Concentration of Use According to Duration and Type of Exposure.11

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>Tetrahexyldecyl Ascorbate</th>
<th>Ascorbyl Linoleate</th>
<th>Ascorbyl Tetraisopalmitate</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td># of Uses</td>
<td>Conc. (%)</td>
<td># of Uses</td>
</tr>
<tr>
<td>Totals/Conc. Range</td>
<td>397</td>
<td>NS</td>
<td>3</td>
</tr>
<tr>
<td>Duration of Use</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leave-On</td>
<td>356</td>
<td>NS</td>
<td>3</td>
</tr>
<tr>
<td>Rinse off</td>
<td>41</td>
<td>NS</td>
<td>NR</td>
</tr>
<tr>
<td>Diluted for (bath) Use</td>
<td>NR</td>
<td>NS</td>
<td>NR</td>
</tr>
<tr>
<td>Exposure Type</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye Area</td>
<td>38</td>
<td>NS</td>
<td>NR</td>
</tr>
<tr>
<td>Incidental Ingestion</td>
<td>96</td>
<td>NS</td>
<td>NR</td>
</tr>
<tr>
<td>Incidental Inhalation-Sprays</td>
<td>6</td>
<td>NS</td>
<td>NR</td>
</tr>
<tr>
<td>Incidental Inhalation-Powders</td>
<td>14</td>
<td>NS</td>
<td>NR</td>
</tr>
<tr>
<td>Dermal Contact</td>
<td>287</td>
<td>NS</td>
<td>3</td>
</tr>
<tr>
<td>Deodorant (underarm)</td>
<td>NR</td>
<td>NS</td>
<td>NR</td>
</tr>
<tr>
<td>Hair - Non-Coloring</td>
<td>10</td>
<td>NS</td>
<td>NR</td>
</tr>
<tr>
<td>Hair-Coloring</td>
<td>NR</td>
<td>NS</td>
<td>NR</td>
</tr>
<tr>
<td>Nail</td>
<td>NR</td>
<td>NS</td>
<td>NR</td>
</tr>
<tr>
<td>Mucous Membrane</td>
<td>108</td>
<td>NS</td>
<td>NR</td>
</tr>
<tr>
<td>Baby Products</td>
<td>NR</td>
<td>NS</td>
<td>NR</td>
</tr>
<tr>
<td>Ascorbyl Dipalmitate</td>
<td>NR</td>
<td>NS</td>
<td>616</td>
</tr>
<tr>
<td>Ascorbyl Palmitate</td>
<td>4</td>
<td>NS</td>
<td>2035</td>
</tr>
<tr>
<td>Ascorbyl Stearate</td>
<td>NR</td>
<td>NS</td>
<td>148</td>
</tr>
<tr>
<td>Dermal Contact</td>
<td>4</td>
<td>NS</td>
<td>1489</td>
</tr>
<tr>
<td>Incidental Inhalation-Sprays</td>
<td>NR</td>
<td>NS</td>
<td>NR</td>
</tr>
<tr>
<td>Incidental Inhalation-Powders</td>
<td>4</td>
<td>NS</td>
<td>102</td>
</tr>
<tr>
<td>Incidental Ingestion</td>
<td>NR</td>
<td>NS</td>
<td>377</td>
</tr>
<tr>
<td>Incidental Ingestion</td>
<td>NR</td>
<td>NS</td>
<td>15</td>
</tr>
<tr>
<td>Incidental Ingestion</td>
<td>NR</td>
<td>NS</td>
<td>64</td>
</tr>
<tr>
<td>Incidental Ingestion</td>
<td>NR</td>
<td>NS</td>
<td>11</td>
</tr>
<tr>
<td>Incidental Ingestion</td>
<td>NR</td>
<td>NS</td>
<td>20</td>
</tr>
<tr>
<td>Incidental Ingestion</td>
<td>NR</td>
<td>NS</td>
<td>387</td>
</tr>
<tr>
<td>Incidental Ingestion</td>
<td>NR</td>
<td>NS</td>
<td>6</td>
</tr>
</tbody>
</table>

NR = Not Reported; Totals = Rinse-off + Leave-on + Diluted for Use Product Uses; NS = Surveyed, but the data have not been received
*It is possible that these products may be sprays, but it is not specified whether the reported uses are sprays.
**It is possible that these products may be powders, but it is not specified whether the reported uses are powders.
***Not specified whether a powder or spray, so this information is captured for both categories of incidental inhalation.

Note: Because each ingredient may be used in cosmetics with multiple exposure types, the sum of all exposure type uses may not equal the sum total uses.
References


